Across Kingdoms: The Bacteriome, Mycobiome, and Virome in Autoimmune Diseases: Mechanistic Insights, Therapeutic Perspectives, and the Emerging Role of COVID-19.

Publication date: Jun 22, 2026

Autoimmune and immune-mediated inflammatory diseases (IMIDs) develop when genetically and environmentally susceptible hosts lose stable immune tolerance. The gut ecosystem is increasingly recognized as a biologically active interface in this process. Its bacterial, fungal, and viral components may shape mucosal and systemic immunity through antigenic stimulation, barrier regulation, and metabolite-dependent signaling, although the strength of evidence is uneven: bacteriome data are currently the most mature, whereas mycobiome, virome, and phageome findings remain more disease-specific and emerging. Dysbiosis may influence autoimmunity through overlapping routes, including epithelial barrier failure, altered short-chain fatty acid, bile acid, and tryptophan metabolism, molecular mimicry, and cross-kingdom microbial interactions. Nutrition is central to this network because dietary substrates determine microbial growth, metabolic output, epithelial integrity, and immune-cell differentiation. In this narrative review, we integrate evidence on disease-associated bacteriome, mycobiome, and virome patterns in systemic autoimmune diseases, with emphasis on rheumatoid arthritis, systemic lupus erythematosus, SjcF6gren’s syndrome, systemic sclerosis, spondyloarthritis, vasculitides, and idiopathic inflammatory myopathies. COVID-19 is considered not as a proven causal driver of autoimmunity, but as an example of an environmental and infectious insult capable of perturbing microbiome-barrier-immune communication. Finally, we discuss diet-based and microbiome-targeted approaches, including probiotics, prebiotics, synbiotics, and postbiotics, as adjunctive strategies that may help restore microbial resilience and immune balance. A better understanding of the diet-microbiome-host immunity axis may support more personalized preventive and therapeutic concepts in autoimmune disease.

Open Access PDF

Concepts Keywords
Autoimmune Autoimmune Diseases
Fungal autoimmunity
Idiopathic COVID-19
Probiotics COVID-19
Viral diet
Dysbiosis
Gastrointestinal Microbiome
Humans
microbiome
nutrition
postbiotics
probiotics
rheumatoid arthritis
SARS-CoV-2
systemic autoimmune diseases
systemic lupus erythematosus
Virome

Semantics

Type Source Name
disease MESH Autoimmune Diseases
disease MESH COVID-19
disease MESH Dysbiosis
pathway KEGG Tryptophan metabolism
disease MESH rheumatoid arthritis
pathway KEGG Rheumatoid arthritis
disease MESH systemic lupus erythematosus
pathway KEGG Systemic lupus erythematosus
disease MESH syndrome
disease MESH systemic sclerosis
disease MESH vasculitides
disease MESH idiopathic inflammatory myopathies
drug DRUGBANK Isoxaflutole
drug DRUGBANK Tropicamide
disease MESH ext
disease MESH arthritis
disease MESH pSS
disease MESH polymyositis dermatomyositis
disease MESH MCTD
disease MESH genetic predisposition
disease MESH infections
pathway REACTOME Fatty acids
drug DRUGBANK L-Tryptophan
disease MESH inflammation
pathway REACTOME Immune System
disease MESH included
disease MESH polymyositis
disease MESH dis
pathway KEGG Tight junction
drug DRUGBANK Pectin
disease MESH endotoxemia
disease MESH LPS
pathway REACTOME Apoptosis
pathway REACTOME Release
disease MESH aspergillosis
drug DRUGBANK Ethanol
disease MESH injury
disease MESH alcoholic hepatitis
pathway REACTOME Metabolism
drug DRUGBANK Butyric Acid
disease MESH insulin resistance
pathway KEGG Insulin resistance
disease MESH dyslipidemia
disease MESH fibrosis
disease MESH Systemic vasculitides
disease MESH IgA vasculitis
disease MESH Kawasaki disease
disease MESH ANCA associated vasculitis
disease MESH synovitis
disease MESH Felty syndrome
disease MESH scleritis
disease MESH lung disease
disease MESH glomerulonephritis
disease MESH osteoporosis
drug DRUGBANK Methotrexate
disease MESH back pain
disease MESH sacroiliitis
disease MESH ankylosing spondylitis
disease MESH psoriasis
disease MESH reactive arthritis
drug DRUGBANK Coenzyme M
disease MESH lupus nephritis
pathway KEGG Oxidative phosphorylation
disease MESH esophageal dysmotility
disease MESH gastroparesis
disease MESH pancreatic insufficiency
disease MESH celiac disease
disease MESH primary biliary cholangitis
disease MESH hyposalivation
disease MESH anxiety
disease MESH pain
disease MESH diarrhea
disease MESH malnutrition
disease MESH fecal incontinence
drug DRUGBANK Acetate ion
drug DRUGBANK Ribostamycin
disease MESH rheumatic diseases
disease MESH strains
disease MESH inclusion body myositis
disease MESH myalgia
disease MESH rhabdomyolysis
drug DRUGBANK Omega-3 fatty acids
drug DRUGBANK Sulodexide
disease MESH arteritis
disease MESH stenosis
disease MESH stroke
disease MESH Polymyalgia rheumatica
disease MESH Takayasu arteritis
drug DRUGBANK Olive oil
drug DRUGBANK Oleic Acid
drug DRUGBANK Fish oil
drug DRUGBANK Icosapent
drug DRUGBANK Doconexent
drug DRUGBANK Galactose
pathway REACTOME Vitamins
disease MESH Raynaud phenomenon
disease MESH digital ulcers
disease MESH gastroesophageal reflux
disease MESH AIP
disease MESH Hashimoto thyroiditis
disease MESH IBS
disease MESH critical illness
disease MESH viral infections
pathway REACTOME Interferon Signaling
disease MESH dys
drug DRUGBANK Trestolone
disease MESH inflammatory bowel disease
pathway KEGG Inflammatory bowel disease
disease MESH interstitial lung disease
pathway KEGG Neutrophil extracellular trap formation
drug DRUGBANK Aminohippuric acid
disease MESH pulmonary arterial hypertension
disease MESH severe acute respiratory syndrome
drug DRUGBANK Vorinostat
disease MESH metabolic diseases
disease MESH Obesity
disease MESH heart failure
drug DRUGBANK Guanosine
disease MESH colitis
disease MESH Kidney Diseases
disease MESH spondylarthritis
disease MESH Spondyloarthropathies
disease MESH Candida Infection
drug DRUGBANK (S)-Des-Me-Ampa
disease MESH RMD
disease MESH Park
disease MESH IgA nephropathy
disease MESH Allergy
drug DRUGBANK Sulfasalazine
disease MESH axial spondyloarthritis
disease MESH AME
disease MESH Diffuse Systemic Sclerosis
disease MESH sarcoidosis
disease MESH Sjogren’s syndrome
disease MESH microscopic polyangiitis
drug DRUGBANK Palmitic Acid
pathway REACTOME Eicosanoids
disease MESH Tam

Original Article

(Visited 3 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *